Unit
Genome Integrity, RNA and Cancer (UMR3348)
Thematic areas of research:
Image
To top
Unit
STEPHAN VAGNER / SARAH LAMBERT
Genome Integrity, RNA and Cancer (UMR3348)
The research conducted at the « Genome Integrity, RNA and Cancer » Unit explores multiple aspects of genome dynamics that integrate RNA biology in the context of genome maintenance and expression in normal and pathological situations, including cancer.
Teams
Key figures
25
km from Paris
25
nationalities since 2015
25
INTERNATIONAL EVENTS ORGANISED
Key publications
All publications
-
-
-
The plasticity of mRNA translation during cancer progression and therapy resistanceNature Reviews Cancer
-
-
-
-
-
Proper chromosome alignment depends on BRCA2 phosphorylation by PLK1Nature Communications
-
-
-
Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against CancerClinical Cancer Research
-
-
News
All news
-
New major players in the protection of DNA replication forks are identifiedIn an article published on March 2, 2023, in the journal Molecular Cell, the team led by Sarah Lambert, in collaboration with researchers from the Institute for Integrative Biology of the Cell, revealed a mechanism that ensures the integrity of DNA replication forks. Based on the combination of RNA and the end-joining factor Ku, it represents a potential new therapeutic target to fight cancerous cells.13/03/2023 -
Three research projects at Institut Curie financed by the ERC Synergy GrantThree projects at Institut Curie are laureate of the highly selective and prestigious Synergy Grant 2022 program, awarded by the European Research Council. These three grants, for an amount of 10 million euros each, shine a light on Institut Curie’s excellence and its teams in cellular biology. A breakthrough field to further the fight against cancer.28/10/2022 -
Carsten Janke awarded an ERC Advanced GrantLong-neglected, research on post-translational modifications of microtubules is now a promising field, thanks in particular to Carsten Janke, a world expert in this area. His excellence in this discipline and the hopes placed in his research have been recognized by the European Research Council (ERC).12/08/2022 -
Albertas Navickas, using organoids to better understand metastatisNewly arrived at Institut Curie, Albertas Navickas, a new Junior Principal Investigator, is working on breast cancer and preparing to form an RNA, tumor microenvironment and metastasis team, reporting to the Genome integrity, RNA and Cancer unit (CNRS UMR3348/University Paris-Saclay), at Orsay.03/05/2022 -
Une nouvelle approche pour décrypter la dynamique des microtubulesL'Institut Curie vient de développer une nouvelle approche pour optimiser l’analyse de la dynamique du cytosquelette et celle des protéines interagissant avec les microtubules. Elle ouvre des perspectives de compréhension de mécanismes clefs en biologie et de phénomènes pathologiques survenant lors des mutations des protéines associées aux microtubules (MAP).01/02/2022 -
Aglaia Therapeutics devient Ribonexus et signe avec Pierre Fabre un accord de licence exclusif portant sur de petites molécules ciblant la protéine eIF4A, une nouvelle cible en oncologieRibonexus (anciennement Aglaia Therapeutics), une entreprise de biotechnologie développant de nouveaux traitements capables de contrer la résistance aux thérapies ciblées chez les patients atteints de cancer, et le groupe pharmaceutique français Pierre Fabre annoncent aujourd’hui la signature d’un accord de licence exclusif portant sur une série de petites molécules brevetées par Pierre Fabre qui ciblent le facteur d’initiation eukaryotique de la traduction 4A (eIF4A). Fortement exprimée dans plusieurs cancers solides et hématologiques, notamment le mélanome, cette cible est associée à une résistance à de nombreuses thérapies actuelles.18/11/2021
Scientific events
All scientific events
15 Dec
2022
Seminar
11h-12h
Advances on Human Topoisomerases IIIA and IIIB, the Most Ancestral and Least Known Topoisomerases
Human cells encode 6 topoisomerases to regulate the topology of nucleic acids. While yeast has only one Top3, mammals encode two Type IA topoisomerases: topoisomerase III alpha (TOP3A) and topoisomerase III beta (TOP3B). We will review the importance of these two enzymes and present new insights on their biochemistry, molecular structure, and biological functions for replicating the nuclear and mi
23 Nov
2022
Seminar
11h-23h
Seeing is believing: break-induced mitotic recombination from 1936 to 2022
And online: Click here to join by Teams